Search results

Skip to results

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Showing 1 to 3 of 3 results for irbesartan

  1. Sparsentan for treating primary IgA nephropathy [ID6308]

    In development [GID-TA11359] Expected publication date: 25 June 2025

    Technology appraisal guidance
    In development

  2. Targeted-release budesonide for treating primary IgA nephropathy (review of TA937) [ID6485]

    In development [GID-TA11662] Expected publication date: 17 December 2025

    Technology appraisal guidance
    In development

  3. Irbesartan–propagermanium for treating focal segmental glomerulosclerosis in people 12 years and over having an angiotensin II receptor blocker [ID6469]

    Awaiting development [GID-TA11575] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development